磁共振成像引导与计算机断层扫描引导的前列腺癌立体定向体部放疗:MIRAGE随机临床试验
MIRAGE 3期随机临床试验在单中心纳入156例临床局限性前列腺癌患者,1:1随机接受CT引导(4 mm margins)或MRI引导(2 mm margins)的40 Gy/5次SBRT。MRI组急性≥2级泌尿生殖毒性显著低于CT组(24.4% vs 43.4%,P=0.01),≥2级胃肠道毒性亦显著降低(0.0% vs 10.5%,P=0.003)。
要点
- MRI引导较CT引导显著降低急性≥2级泌尿生殖毒性(24.4% vs 43.4%,P=0.01)。
- MRI引导较CT引导显著降低急性≥2级胃肠道毒性(0.0% vs 10.5%,P=0.003)。
- MRI组1个月时IPSS≥15分增加及EPIC-26肠道评分≥12分下降比例均显著低于CT组。
核心结论
- 在該随机临床试验中,与CT引导相比,MRI引导SBRT显著降低中度急性医生评分的毒性及患者报告生活质量下降。
- 更长期随访将确认这些显著获益是否持续。
研究设计与样本
- 3期随机临床试验(MIRAGE),于2020年5月5日至2021年10月1日在单中心入组18岁及以上接受SBRT的临床局限性前列腺腺癌男性。
- 共156例患者1:1随机:CT引导组77例(中位年龄71岁,IQR 67-77岁),MRI引导组79例(中位年龄71岁,IQR 68-75岁)。
- CT组计划 margins 4 mm,MRI组2 mm,均给予40 Gy分5次。
- 预设无效性中期分析在100例患者达到SBRT后≥90天时于2021年10月1日进行,样本量重新估计为154例,试验提前停止入组。
- 所有患者随访≥3个月。
主要发现
- 急性(SBRT后≤90天)≥2级泌尿生殖毒性发生率MRI组24.4%(95%CI 15.4%-35.4%)vs CT组43.4%(95%CI 32.1%-55.3%),P=0.01。
- 急性≥2级胃肠道毒性发生率MRI组0.0%(95%CI 0.0%-4.6%)vs CT组10.5%(95%CI 4.7%-19.7%),P=0.003。
- 1个月时IPSS增加≥15分的患者比例MRI组6.8%(5/72)vs CT组19.4%(14/74),P=0.01。
- 1个月时EPIC-26肠道评分临床显著(≥12分)下降的患者比例MRI组25.0%(17/68)vs CT组50.0%(34/68),P=0.001。
关键数值与推荐
- 主要终点为急性(≤90天)≥2级泌尿生殖毒性,采用CTCAE v4.03。
- 次要终点包括CTCAE v4.03胃肠道毒性、IPSS及EPIC-26结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验为单中心。
- 因预设无效性中期分析后样本量重新估计为154例,试验提前停止入组。
- 更长期随访将确认这些显著获益是否持续。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Magnetic resonance imaging (MRI) guidance offers multiple theoretical advantages in the context of stereotactic body radiotherapy (SBRT) for prostate cancer. However, to our knowledge, these advantages have yet to be demonstrated in a randomized clinical trial. OBJECTIVE: To determine whether aggressive margin reduction with MRI guidance significantly reduces acute grade 2 or greater genitourinary (GU) toxic effects after prostate SBRT compared with computed tomography (CT) guidance. DESIGN, SETTING, AND PARTICIPANTS: This phase 3 randomized clinical trial (MRI-Guided Stereotactic Body Radiotherapy for Prostate Cancer [MIRAGE]) enrolled men aged 18 years or older who were receiving SBRT for clinically localized prostate adenocarcinoma at a single center between May 5, 2020, and October 1, 2021. Data were analyzed from January 15, 2021, through May 15, 2022. All patients had 3 months or more of follow-up. INTERVENTIONS: Patients were randomized 1:1 to SBRT with CT guidance (control arm) or MRI guidance. Planning margins of 4 mm (CT arm) and 2 mm (MRI arm) were used to deliver 40 Gy in 5 fractions. MAIN OUTCOMES AND MEASURES: The primary end point was the incidence of acute (≤90 days after SBRT) grade 2 or greater GU toxic effects (using Common Terminology Criteria for Adverse Events, version 4.03 [CTCAE v4.03]). Secondary outcomes included CTCAE v4.03-based gastrointestinal toxic effects and International Prostate Symptom Score (IPSS)-based and Expanded Prostate Cancer Index Composite-26 (EPIC-26)-based outcomes. RESULTS: Between May 2020 and October 2021, 156 patients were randomized: 77 to CT (median age, 71 years [IQR, 67-77 years]) and 79 to MRI (median age, 71 years [IQR, 68-75 years]). A prespecified interim futility analysis conducted after 100 patients reached 90 or more days after SBRT was performed October 1, 2021, with the sample size reestimated to 154 patients. Thus, the trial was closed to accrual early. The incidence of acute grade 2 or greater GU toxic effects was significantly lower with MRI vs CT guidance (24.4% [95% CI, 15.4%-35.4%] vs 43.4% [95% CI, 32.1%-55.3%]; P = .01), as was the incidence of acute grade 2 or greater gastrointestinal toxic effects (0.0% [95% CI, 0.0%-4.6%] vs 10.5% [95% CI, 4.7%-19.7%]; P = .003). Magnetic resonance imaging guidance was associated with a significantly smaller percentage of patients with a 15-point or greater increase in IPSS at 1 month (6.8% [5 of 72] vs 19.4% [14 of 74]; P = .01) and a significantly reduced percentage of patients with a clinically significant (≥12-point) decrease in EPIC-26 bowel scores (25.0% [17 of 68] vs 50.0% [34 of 68]; P = .001) at 1 month. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, compared with CT-guidance, MRI-guided SBRT significantly reduced both moderate acute physician-scored toxic effects and decrements in patient-reported quality of life. Longer-term follow-up will confirm whether these notable benefits persist. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04384770.
引用
- Kishan AU, Ma TM, Lamb JM, et al. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 36633877. doi:10.1001/jamaoncol.2022.6558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。